Blockade of PD-1 or PD-L1 to inhibit T cell effector suppression by ligand engagement is increasingly used in the context of anti-tumour immunotherapy where it is effective against tumours with demonstrable PD-L1 expression, but its effectiveness in infectious disease has not been well explored (2, 3). Here, CD274 is linked to neoplasm.